Loading clinical trials...
Loading clinical trials...
The objective of this trial is to determine the effect of linaclotide on abdominal girth in IBS-C participants with the baseline symptoms of abdominal bloating and an increased abdominal girth.
Keep your clinical trial research organized — questions to ask, what to expect, and key details.
Lead Sponsor
Ironwood Pharmaceuticals, Inc.
Collaborators
NCT03687814 · Irritable Bowel Syndrome Characterized by Constipation
NCT02387359 · Irritable Bowel Syndrome Characterized by Constipation
NCT01722318 · Irritable Bowel Syndrome Characterized by Constipation
NCT01622972 · Functional Constipation, Irritable Bowel Syndrome Characterized by Constipation
Peter Whorwell
Wythenshawe, Manchester
Use Clareo to keep notes, questions, trial details, and next steps organized before and after appointments.
Start free trial →Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions